Continuous intraperitoneal insulin infusion in type 1 diabetes: a 6-year post-trial follow-up
Open Access
- 7 April 2014
- journal article
- research article
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 14 (1) , 30
Abstract
Continuous intraperitoneal insulin infusion (CIPII) with an implantable pump is a treatment option for patients with type 1 diabetes mellitus (T1DM). Aim of the present study was to describe the long-term course of glycaemic control, complications, health related quality of life (HRQOL) and treatment satisfaction among T1DM patients treated with CIPII.Keywords
This publication has 23 references indexed in Scilit:
- Health-Related Quality of Life, Treatment Satisfaction, and Costs Associated With Intraperitoneal Versus Subcutaneous Insulin Administration in Type 1 DiabetesDiabetes Care, 2010
- Improved Glycemic Control With Intraperitoneal Versus Subcutaneous Insulin in Type 1 DiabetesDiabetes Care, 2009
- Glycaemic control, health status and treatment satisfaction with continuous intraperitoneal insulin infusion.2007
- Measuring well‐being rather than the absence of distress symptoms: a comparison of the SF‐36 Mental Health subscale and the WHO‐Five well‐being scaleInternational Journal of Methods in Psychiatric Research, 2003
- Comparison of blood glucose stability and HBA1c between implantable insulin pumps using U400 Hoe 21ph insulin and external pumps using lispro in type 1 diabetic patients: A pilot study2002
- Increased responses of glucagon and glucose production to hypoglycemia with intraperitoneal versus subcutaneous insulin treatmentMetabolism, 2000
- Continuous intraperitoneal insulin infusion partly restores the glucagon response to hypoglycaemia in type 1 diabetic patients2000
- Feasibility of Intraperitoneal Insulin Therapy With Programmable Implantable Pumps in IDDM: A multicenter studyDiabetes Care, 1995
- The MOS 36-Item Short-Form Health Survey (SF-36)Medical Care, 1993
- The kinetics of peritoneal insulin absorptionMetabolism, 1981